

## **SGLT2 inhibitors – looking beyond glucose-lowering in diabetes**

### **References**

1. Lo, C. *et al.* Insulin and glucose-lowering agents for treating people with diabetes and chronic kidney disease. *Cochrane Database Syst. Rev.* (2018). doi:10.1002/14651858.CD011798.pub2
2. Zinman, B. *et al.* Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. *N. Engl. J. Med.* **373**, 2117–2128 (2015).
3. Neal, B. *et al.* Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. *N. Engl. J. Med.* **377**, 644–657 (2017).
4. Wiviott, S. *et al.* Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. *N. Engl. J. Med.* **380**, 347–357 (2019).
5. Mudaliar, S., Polidori, D., Zambrowicz, B. & Henry, R. R. Sodium-glucose cotransporter inhibitors: Effects on renal and intestinal glucose transport from bench to bedside. *Diabetes Care* **38**, 2344–2353 (2015).
6. Wright, E. M., Loo, D. D. F., Hirayama, B. A. & Human, C. Biology of Human Sodium Glucose Transporters. *Physiol. Rev.* **91**, 733–794 (2011).
7. Chen, J. *et al.* Quantitative PCR tissue expression profiling of the human SGLT2 gene and related family members. *Diabetes Ther.* **1**, 57–92 (2010).
8. Perrone-Filardi, P. *et al.* Mechanisms linking empagliflozin to cardiovascular and renal protection. *Int. J. Cardiol.* **241**, 450–456 (2017).
9. Nissen, S. E. & Wolski, K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. *N. Engl. J. Med.* **356**, 2457–71 (2007).
10. Marks, D. H. Drug utilization, safety and clinical use of Actos and Avandia. *Int. J. Risk Saf. Med.* **25**, 39–51 (2013).
11. FDA. Guidance for industry diabetes mellitus—evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes. *Silver Spring* (2008).
12. EMA. Guideline on clinical investigation of medicinal products in the treatment or prevention of diabetes mellitus. *London* (2012).
13. Mannucci, E., Mosenzon, O. & Avogaro, A. Analyses of Results From

Cardiovascular Safety Trials With DPP-4 Inhibitors : Cardiovascular Outcomes , Predefined Safety Outcomes , and Pooled Analysis and Meta-analysis. *Diabetes Care* **39**, 196–204 (2016).

14. Ueda, P. *et al.* Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: nationwide register based cohort study. *BMJ* **363**, (2018).
15. McMurray, J. J. V. *et al.* Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. *N. Engl. J. Med.* **381**, 1995–2008 (2019).
16. Perkovic, V. *et al.* Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. *N. Engl. J. Med.* **380**, 2295–2306 (2019).